Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120’s Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines
Genes · 2024
DOI: 10.3390/genes15020202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Yu Gao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Foundation, 30559 Hannover, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Melanoma, Phenylurea Compounds, Pyrimidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The China Scholarship Council (CSC).
Abstract (Originalsprache)
Malignant melanomas (MMs) are the abnormal proliferation of melanocytes and are one of the lethal skin cancers in humans, equines, and canines. Accordingly, MMs in companion animals can serve as naturally occurring animal models, completing conventional cancer models. The common constitutive activation of the MAPK and PI3K pathways in MMs has been described in all three species. Targeting the related pathways is considered a potential option in comparative oncologic approaches. Herein, we present a cross-species comparative analysis exposing a set of ten melanoma cell lines (one human, three equine, and six canine) derived from primary tumors or metastasis to a pan-RAF and RAF dimer inhibitor (LY3009120). Cellular response (proliferation, biomass, metabolism, early and late apoptosis/necrosis, and morphology) and the presence of pathogenic single-nucleotide variants (SNVs) within the mutational hotspot genes BRAF exon 11 and 15, NRAS exon 2 and 3, KRAS exon 2, and KIT exon 11 were analyzed. This study showed that equine malignant melanoma (EMM) cells (MelDuWi) harbor the KRAS p.Q61H mutation, while canine malignant melanoma (CMM) cells (cRGO1 and cRGO1.2) carry NRAS p.G13R. Except for EMM metastasis cells eRGO6 (wild type of the above-mentioned hotspot genes), all melanoma cell lines exhibited a decrease in dose dependence after 48 and 72 h of exposure to LY3009120, independent of the mutation hotspot landscape. Furthermore, LY3009120 caused significant early apoptosis and late apoptosis/necrosis in all melanoma cell lines except for eRGO6. The anti-tumor effects of LY3009120 were observed in nine melanoma cell lines, indicating the potential feasibility of experimental trials with LY3009120. The present study reveals that the irradiation-resistant canine metastasis cells (cRGO1.2) harboring the NRAS p.G13R mutation are significantly LY3009120-sensitive, while the equine metastases-derived eRGO6 cells show significant resistance to LY3009120, which make them both valuable tools for studying resistance mechanisms in comparative oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Foundation, 30559 Hannover, Germany.
- Department of Medicine, Clinic III, Hematology, Oncology and Palliative Medicine, University Medical Center Rostock, 18057 Rostock, Germany.
- Clinical Unit of Equine Internal Medicine, Department for Companion Animals and Horses, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.
- Clinical Unit of Small Animal Internal Medicine, Department for Companion Animals and Horses, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.
- Institute of Pathology, University Medicine of Rostock, Strempelstrasse, 18055 Rostock, Germany.
- Institute of Veterinary Medicine, Division of Molecular Biology of Livestock and Molecular Diagnostics, Georg-August-University of Göttingen, 37077 Göttingen, Germany.
ORCID-Profile: Yu Gao, Eva-Maria Packeiser, Jessika-Maximiliane V Cavalleri, Barbara Pratscher, Maja Hühns, Bertram Brenig, Hugo Murua Escobar
Förderung
- The China Scholarship Council (CSC)
Zitieren
APA
Gao, Y., Packeiser, E. M., Wendt, S., Sekora, A., Cavalleri, J. V., Pratscher, B., Alammar, M., Hühns, M., Brenig, B., Junghanss, C., Nolte, I., & Murua Escobar, H. (2024). Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120’s Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines. Genes. https://doi.org/10.3390/genes15020202
Vancouver
Gao Y, Packeiser EM, Wendt S, Sekora A, Cavalleri JV, Pratscher B, et al. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120’s Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines. Genes. 2024. doi:10.3390/genes15020202
BibTeX
@article{Gao2024,
author = {Gao, Yu and Packeiser, Eva-Maria and Wendt, Sophia and Sekora, Anett and Cavalleri, Jessika-Maximiliane V and Pratscher, Barbara and Alammar, Moosheer and Hühns, Maja and Brenig, Bertram and Junghanss, Christian and Nolte, Ingo and Murua Escobar, Hugo},
title = {Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120’s Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15020202}
}
EUVIMED